Avalanche Biotechnologies Receives New Coverage from Analysts at Jefferies Group (AAVL)
Jefferies Group assumed coverage on shares of Avalanche Biotechnologies (NASDAQ:AAVL) in a research note issued on Monday. The firm set a “buy” rating and a $40.00 price target on the stock. Jefferies Group’s price objective would suggest a potential upside of 31.06% from the stock’s previous close.
Avalanche Biotechnologies (NASDAQ:AAVL) opened at 30.52 on Monday. Avalanche Biotechnologies has a 52 week low of $22.00 and a 52 week high of $32.375. The stock’s 50-day moving average is $26.28 and its 200-day moving average is $26.28. The company’s market cap is $651.9 million.
Avalanche Biotechnologies, Inc (NASDAQ:AAVL) is a biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.